Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00358956 · ClinicalTrials.gov registry record · Phase 2
A Study To Assess ZD6474 (ZACTIMA™) Monotherapy In Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer
A Phase 2 study, sponsored by Genzyme, a Sanofi Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 19
- Enrollment target
NCT00358956 is a Phase 2 study that has completed, run by Genzyme, a Sanofi Company. The registered enrollment target is 19 participants.
The verdict
NCT00358956, a Phase 2 study, has completed, sponsored by Genzyme, a Sanofi Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 19 participants
- Enrollment target
Study Summary
This will be a Phase II, open label study to establish the effect of once-daily oral doses of ZD6474 100mg in subjects with locally advanced or metastatic hereditary medullary thyroid cancer in whom no standard therapeutic option is available.
Interventions
- DRUG ZD6474 (vandetanib)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2006-08 |
| Est. Completion | 2014-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00358956
The ClinicalTrials.gov registry entry for NCT00358956 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genzyme, a Sanofi Company, which has 196 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ZD6474 (vandetanib) is the first listed.
NCT00358956 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00358956 about?
NCT00358956 is a clinical study titled "A Study To Assess ZD6474 (ZACTIMA™) Monotherapy In Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer". This will be a Phase II, open label study to establish the effect of once-daily oral doses of ZD6474 100mg in subjects with locally advanced or metastatic hereditary medullary thyroid cancer in whom no standard therapeutic option is available.
What is the current status of trial NCT00358956?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 2006-08. Estimated completion is 2014-05.
What interventions are being tested in trial NCT00358956?
The interventions under investigation include: ZD6474 (vandetanib) (DRUG).
Who is sponsoring clinical trial NCT00358956?
This trial is sponsored by Genzyme, a Sanofi Company, which has 196 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.